Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor
Novartis’s $9.7 Billion Purchase Includes Novel PCSK9 Inhibitor

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

The pharmaceutical firm is buying The Medicines Company, which recently devoted its efforts into developing the cholesterol-lowering medication.

mergers and acquisition
UCB Cuts $2.1 Billion Deal to Acquire Ra Pharma
Catherine Offord | Oct 14, 2019 | 2 min read
The move will allow the Belgium-headquartered biopharmaceutical giant to boost its work on treatments for rare diseases.
Bristol-Myers Squibb to Buy Celgene for $74 Billion
Catherine Offord | Jan 3, 2019 | 1 min read
The deal between the two biopharmaceutical giants will boost the purchaser’s cancer drug portfolio.
Gilead to Pay Nearly $12B for CAR T-Cell Company
Jef Akst | Aug 28, 2017 | 2 min read
The massive sum will buy out Kite Pharma, whose cancer therapy is expected to be among the first of its type approved by the FDA.
Thermo Fisher to Buy Patheon for $5.2 Billion
Aggie Mika | May 16, 2017 | 2 min read
The scientific supply giant seeks to expand into biopharma development and manufacturing.  
Monsanto and Bayer Announce Approval of Massive Merger
Bob Grant | Dec 13, 2016 | 2 min read
On Tuesday, shareholders at the agribusiness giant approved the $66 billion deal with the European pharmaceutical firm.
Novartis Buys US Drugmaker for Up To $665 Million
Tracy Vence | Nov 22, 2016 | 1 min read
The Swiss pharma giant is acquiring Oklahoma-based Selexys Pharmaceuticals, a maker of drugs for inflammatory and thrombotic diseases.
Allergan’s Buying Spree Rolls On
Bob Grant | Sep 21, 2016 | 2 min read
The Ireland-based pharma company makes a $1.7 billion offer to acquire Tobira Therapeutics, a US firm developing liver disease drugs.
Allergan Set to Buy Vitae
Bob Grant | Sep 16, 2016 | 1 min read
The Irish drugmaker has made a $639 million dollar offer to buy the US-based biopharma.
Bayer Looks to Buy Monsanto
Bob Grant | Sep 14, 2016 | 1 min read
The US agribusiness behemoth agreed to a $57 billion buyout offer from the European pharmaceutical giant.
Pfizer to Buy Medivation for $14 Billion
Bob Grant | Aug 22, 2016 | 1 min read
The pharma giant is purchasing the San Francisco–based cancer drugmaker to boost its oncology portfolio.
TS Picks: June 6, 2016
Jef Akst | Jun 6, 2016 | 2 min read
American Society of Clinical Oncology meeting edition 
$1.5 Billion Pharma Buyout for Leukemia Drug
Jef Akst | Jun 1, 2016 | 1 min read
Jazz Pharmaceuticals is set to purchase Celator to acquire an experimental treatment for acute myeloid leukemia.
Thermo Fisher to Acquire FEI
Tracy Vence | Jun 1, 2016 | 1 min read
In a $4.2 billion deal, the science equipment giant is buying the Hillsboro, Oregon-based electron microscope maker.
Pfizer Scoops Anacor for $5.3 Billion
Bob Grant | May 17, 2016 | 2 min read
The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.
Pfizer-Allergan Merger Scrapped
Bob Grant | Apr 7, 2016 | 2 min read
A move by the US federal government to close tax loopholes that encourage “tax inversions” likely spooked the companies out of the multibillion dollar deal.
Former Affymetrix Employees Fail to Stop Thermo Fisher Takeover
Bob Grant | Mar 22, 2016 | 2 min read
Their $1.5 billion bid, which topped Thermo Fisher Scientific’s $1.3 billion offer for the genetic analysis company, was rejected.
Abbott Acquires Diagnostics Firm
Kerry Grens | Feb 2, 2016 | 1 min read
In a deal worth $5.8 billion, Abbott Laboratories is buying medical test–maker Alere.
Shire to Buy Baxalta for $32 Billion
Tracy Vence | Jan 11, 2016 | 1 min read
The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.
Thermo Fisher to Acquire Affymetrix
Tracy Vence | Jan 11, 2016 | 1 min read
The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.